title: Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57].
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Dean
authors.initials: D
authors.lastname: Gilham
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Sylwia
authors.initials: S
authors.lastname: Wasiak
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Laura M
authors.initials: LM
authors.lastname: Tsujikawa
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Christopher
authors.initials: C
authors.lastname: Halliday
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Karen
authors.initials: K
authors.lastname: Norek
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Reena G
authors.initials: RG
authors.lastname: Patel
authors.affiliation: Resverlogix Corp., Calgary, Canada.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Kulikowski
authors.affiliation: Resverlogix Corp., San Francisco, USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Johansson
authors.affiliation: Resverlogix Corp., San Francisco, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Sweeney
authors.affiliation: Resverlogix Corp., Calgary, Canada. Electronic address: norm@resverlogix.com.
authors.forename: Norman C W
authors.initials: NC
authors.lastname: Wong